Takuji Okusaka spends much of his time researching Internal medicine, Gastroenterology, Hepatocellular carcinoma, Oncology and Pancreatic cancer. Chemotherapy, Phases of clinical research, Gemcitabine, Survival rate and Hazard ratio are the primary areas of interest in his Internal medicine study. His research integrates issues of Radiation therapy, Surgery, Adverse effect, Neutropenia and Clinical endpoint in his study of Gastroenterology.
His research investigates the connection between Hepatocellular carcinoma and topics such as Carcinoma that intersect with issues in Radiology. His Oncology research includes elements of Cancer, Irinotecan and Survival analysis. His work deals with themes such as Weight loss, Bioinformatics, Carcinogenesis and Pancreatic disease, Pancreas, which intersect with Pancreatic cancer.
Takuji Okusaka mainly focuses on Internal medicine, Oncology, Gastroenterology, Hepatocellular carcinoma and Gemcitabine. His work on Pancreatic cancer, Chemotherapy and Phases of clinical research as part of general Internal medicine research is frequently linked to In patient, bridging the gap between disciplines. His Oncology study incorporates themes from Cancer, Regimen, Clinical trial and Cisplatin.
His research investigates the link between Gastroenterology and topics such as Clinical endpoint that cross with problems in Hazard ratio. His studies deal with areas such as Carcinoma, Ramucirumab and Toxicity as well as Hepatocellular carcinoma. His Gemcitabine study combines topics in areas such as Combination chemotherapy, Chemoradiotherapy, Combination therapy and Antimetabolite.
Internal medicine, Hepatocellular carcinoma, Gastroenterology, Oncology and Sorafenib are his primary areas of study. He integrates many fields, such as Internal medicine and In patient, in his works. His Hepatocellular carcinoma research is multidisciplinary, incorporating perspectives in Carcinoma, Ramucirumab and Objective response.
Takuji Okusaka interconnects Tolerability, Neutropenia, Phases of clinical research and Hazard ratio in the investigation of issues within Gastroenterology. He has researched Oncology in several fields, including Neuroendocrine tumors, Combination chemotherapy, Nivolumab and Predictive marker. His Gemcitabine research integrates issues from Clinical trial, Pancreatic cancer and Cisplatin.
Internal medicine, Hepatocellular carcinoma, Oncology, Gastroenterology and Sorafenib are his primary areas of study. His works in Adverse effect, Clinical endpoint, Gemcitabine, Pancreatic cancer and Hazard ratio are all subjects of inquiry into Internal medicine. His study in the fields of Lenvatinib under the domain of Hepatocellular carcinoma overlaps with other disciplines such as In patient.
Takuji Okusaka has included themes like Combination chemotherapy, Chemotherapy, Nivolumab and Erlotinib in his Oncology study. His research in Gastroenterology intersects with topics in Cancer, Fluorouracil, Carcinoma and Neutropenia. As a member of one scientific family, Takuji Okusaka mostly works in the field of Sorafenib, focusing on Combination therapy and, on occasion, Nausea, Transcatheter arterial chemoembolization, Milan criteria, Tumor progression and ECOG Performance Status.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao;Manisha H. Shah;Tetsuhide Ito;Catherine Lombard Bohas.
The New England Journal of Medicine (2011)
Pan-cancer analysis of whole genomes
Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart.
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.
Y Matsumura;T Hamaguchi;T Ura;K Muro.
British Journal of Cancer (2004)
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators
Akihiro Fujimoto;Yasushi Totoki;Tetsuo Abe;Keith A. Boroevich.
Nature Genetics (2012)
Ramucirumab Versus Placebo as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH): A Randomised, Double-Blind, Multicentre, Phase 3 Trial
Andrew X. Zhu;Joon Oh Park;Baek Yeol Ryoo;Chia Jui Yen.
Lancet Oncology (2015)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu;Yoon-Koo Kang;Chia-Jui Yen;Richard S Finn.
Lancet Oncology (2019)
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa.
Journal of Clinical Oncology (2013)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T Okusaka;K Nakachi;A Fukutomi;N Mizuno.
British Journal of Cancer (2010)
Genomic spectra of biliary tract cancer
Hiromi Nakamura;Yasuhito Arai;Yasushi Totoki;Tomoki Shirota.
Nature Genetics (2015)
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Yasushi Totoki;Kenji Tatsuno;Kyle R. Covington;Hiroki Ueda.
Nature Genetics (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: